Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918941 | 0.89 | ADORA3 (0.42) | ADORA3ADORA2AADORA1ADORA2BNPY5R | |
| SCHEMBL1918924 | 0.80 | ADORA3 (0.47) | ADORA3ADORA2AADORA1NPY5RDHODH | |
| SCHEMBL1918105 | 0.79 | MAPT (0.46) | PRKAG1PRKAA2PRKAB1 | |
| SCHEMBL14395514 | 0.77 | NPY5R (0.47) | NPY5RGAAL3MBTL1PKM | |
| SCHEMBL1918303 | 0.77 | DHODH (0.47) | TDP1DHODH | |
| SCHEMBL31459666 | 0.75 | TDP1 (0.38) | ADORA1TDP1NPSR1 | |
| SCHEMBL5204337 | 0.74 | TDP1 (0.40) | TDP1NPSR1GAAL3MBTL1 | |
| SCHEMBL14097414 | 0.71 | ABL1 (0.65) | — | |
| SCHEMBL22650275 | 0.70 | DHODH (0.49) | ADORA3ADORA2AADORA1DHODHNLRP3 | |
| SCHEMBL7660194 | 0.69 | NPC1 (0.47) | TDP1NPSR1PRKAG1PRKAA2PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081213-B1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO LTD (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-9475805-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| EP-3081213-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20150291587-A1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20130267711-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8486980-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20110201640-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2327690-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291587-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | ADORA3 654/4885ADORA2A 596/4885ADORA1 450/4885 |
| US-20130267711-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | ADORA3 654/4885ADORA2A 596/4885ADORA1 450/4885 |
| US-20110201640-A1 | TRICYCLIC COMPOUND | PPARG, PPARA, PPARD | ADORA3 1519/4885ADORA2A 1624/4885ADORA1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.